Fibromyalgia affects millions of patients worldwide who are often resistant to or cannot tolerate medication
Cincinnati, OH (PRWEB) August 1, 2006
Moeller Medical, LLC announces today its distribution of an FDA-cleared electrical device that effectively treats depression, anxiety, insomnia, and pain.
Unlike traditional ‘shock therapy,’ this treatment, called Cranial Electrotherapy Stimulation (CES), delivers a dose of electricity that is almost undetectable. These “micro-currents” attempt to mimic the body’s own natural electrical function. In doing so, it is thought that they stimulate the areas of the brain responsible for neurotransmitter and hormone production. Most patients report a decrease in symptoms after just one treatment session. This supports clinical studies that show an increase in patients' serotonin and beta-endorphin levels immediately after use.
“Patients with treatment-resistant depression have shown significant elevations in plasma serotonin” said Marshall F. Gilula, M.D. and Paul R. Barach, M.D. from University of Miami’s School of Medicine. “Increases in cerebrospinal fluid level of beta-endorphins up to 219%, plasma endorphins up to 98%, and cerebrospinal fluid serotonin up to 200% have been demonstrated in normal volunteers receiving 20 minutes of CES.”
Interestingly, Cranial Electrotherapy Stimulation is actually very safe compared to most medication. It has almost no side effects and can be used for any age group. In contrast, most antidepressant and anti-anxiety medication on the market now carry ‘Black Box Warning’ labels and many are not approved for use in minors.
With new non-drug treatments emerging such as Transcranial Magnetic Stimulation (TMS) by Neuronetics, Inc. and Vagus Nerve Stimulation (VNS) by Cyberonics, Inc., Moeller Medical thinks it has found a much needed niche in this arena. VNS and TMS therapy, while their actions differ from CES, also provide electrical stimulation of the brain. VNS requires invasive surgery to implant a device which can be very prohibitive for some and TMS is not yet accessible to the public. CES is a readily available, easy to implement treatment for patients.
While its indications are restricted to depression, anxiety, insomnia, and pain, recent research has shown promising results with disorders such as fibromyalgia, migraine headaches, and ADHD.
“We have demonstrated that active treatment with CES results in significant improvement in a number of clinical parameters associated with fibromyalgia. The results of our investigation appear to be most encouraging, given the refractory nature of fibromyalgia pain to conventional pain management,” says Randall C. Cork, M.D., Ph.D., from Louisiana State University’s Health Sciences Center.
“Fibromyalgia affects millions of patients worldwide who are often resistant to or cannot tolerate medication,” said Moeller Medical President and CEO, Karl Moeller. “It is exciting to be able to work toward a positive treatment option for this often debilitating syndrome.”
Moeller Medical has launched two informational web sites for patients and professionals to learn about the device, Depression Treatment Now and Anxiety Treatment Now, and plans to follow up with informative sites later this year for insomnia and pain.
About Moeller Medical, Inc.
Moeller Medical, LLC is a privately held company based in Cincinnati, OH. Moeller Medical is dedicated to bringing safe, quality healthcare products to the patient and medical community and is proud to offer a completely non-invasive drug-free form of psychological and pain treatment. For more information; visit http://www.depressiontreatmentnow.com .
For more information:
President and CEO
Moeller Medical, LLC
513-297-4975 ext. 101
# # #